David Berger
Endocrinology, Diabetes & Metabolism · Downey, CANPI 1881683944
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $61,358 of the $80,955 with a category attached, or 75.8%. 25 manufacturers reported payments, led by Lilly USA, LLC at 49.7% of the total. Reporting peaked in 2019 at $65,005 and has fallen 99.8% since, to $108 in 2025. Among endocrinology, diabetes & metabolism clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 265 payments — averaging $305.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$40K
- Novo Nordisk$20K
- AstraZeneca$16K
- Sanofi-aventis U.S. LLC$3K
- Amgen$390
- AbbVie$280
- plus $2K from 19 others
What the payments were for
- Consulting fees$4,8006%
- Speaking & faculty fees$61,35876%
- Travel & lodging$8,83511%
- Food & beverage$5,8887%
- Education$730%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 109 | $40,226 |
| Novo Nordisk | 42 | $20,114 |
| AstraZeneca | 30 | $15,712 |
| Sanofi-aventis U.S. LLC | 21 | $2,592 |
| Amgen(2 entities) | 10 | $390 |
| AbbVie | 5 | $280 |
| Bayer | 2 | $276 |
| Lexicon Pharmaceuticals, Inc. | 2 | $235 |
| Amarin Pharma, Inc. | 10 | $201 |
| Merck | 9 | $187 |
| Recordati_rare_diseases_inc. | 1 | $155 |
| Ascendis Pharma Endocrinology Inc | 1 | $108 |
| Johnson & Johnson | 6 | $102 |
| Insulet Corporation | 3 | $49 |
| Amerisourcebergen Drug Corporation | 1 | $48 |
| Corcept Therapeutics | 2 | $42 |
| Radius Health, Inc. | 2 | $39 |
| BD | 1 | $37 |
| Acerus Pharmaceuticals Corporation | 1 | $30 |
| Medtronic | 1 | $30 |
| Mannkind Corporation | 2 | $29 |
| IBSA Pharma Inc. | 1 | $23 |
| Boehringer Ingelheim | 1 | $19 |
| Gilead | 1 | $17 |
| Antares Pharma, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$80,955 in reported general payments places this provider in the 95th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Other endocrinology, diabetes & metabolism in Downey
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.